^
    Back
    Association details:
    Biomarker:EGFR mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Fumena (vorolanib) (VEGFR inhibitor, PDGFR inhibitor, Tyrosine kinase inhibitor, CSF-1R inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Thorac Cancer
    Title:

    CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo

    Published date:
    05/06/2020
    Excerpt:
    CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on EGFR mutant NSCLC by inhibiting proliferation and angiogenesis and promoting apoptosis of tumor cells.
    DOI:
    10.1111/1759-7714.13430